Files and links (1)
Published, Version of Record (VoR)CC BY-NC V4.0, Open
Annotation
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial (vol 12, e063650, 2022)
BMJ open, v 13(4), 063650
01 Apr 2023
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The authors want to alert the readers that a typographical error noticed in the abstract and Box 1, has now been corrected.
In the abstract, an end parenthesis “)” was added to separate the FDA acronym from the rest of the sentence.
In Box 1, slight change in wording of the two coprimary endpoints as well as adding two secondary endpoints to align with the PAMPA trial’s posting on clinicaltrial.gov.
Metrics
6 Record Views
Details
- Title
- Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial (vol 12, e063650, 2022)
- Creators
- R. H. Haberman - New York University School of MedicineK. A. MacFarlane - New York UniversityS. Catron - New York University School of MedicineSoumya D Chakravarty - Drexel University, General Internal Medicine
- Publication Details
- BMJ open, v 13(4), 063650
- Publisher
- Bmj Publishing Group
- Number of pages
- 1
- Resource Type
- Annotation
- Language
- English
- Academic Unit
- Rheumatology; General Internal Medicine
- Web of Science ID
- WOS:000992568000003
- Scopus ID
- 2-s2.0-85151889340
- Other Identifier
- 991022048819604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Rheumatology